Hot topics, watchlist, data center, market center, capital flows, and simulated trading client. From October 20 to 22 by the Huangpu River in Shanghai, the 2026 Sustainable Global Leaders Conference will return once again. Nobel Prize and Turing Award winners will take the stage to discuss the future and trends of technology, and the internet-famous professor who "rescues" people from anxiety and the era of involution, Macfarlane, will hold a live dialogue with Xiang Biao!
Limited seats available, first come first served. Let us embark together on the journey of sustainability! [Click to register] GenFleet-B (02595) rose more than 8% intraday. As of the time of writing, the share price has pulled back and is now up 1.82% at HK$26.82, with a turnover of HK$55.9519 million.
On October 15, GenFleet-B issued an announcement that GFH375/VS-7375 (an oral KRAS G12D inhibitor) has achieved positive progress in multiple domestic and overseas clinical studies, and the latest data from the relevant studies have been released. Currently, GFH375 has obtained three Breakthrough Therapy Designations (BTD) in China for the treatment of KRAS G12D-mutant pancreatic cancer, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC), and has entered two registrational Phase III studies for monotherapy in pancreatic cancer and NSCLC.
GenFleet's overseas partner Verastem Oncology (Verastem) is expected to launch a registrational Phase III study of VS-7375 in multiple combination regimens (combined with anti-EGFR therapy or chemotherapy) for first-line treatment of PDAC by the end of this year, with progression-free survival (PFS) and objective response rate (ORR) as dual primary endpoints and overall survival (OS) as a secondary endpoint. It has currently reached consensus with the U.S. Food and Drug Administration (FDA) on the study protocol.
Comments